INNOVA CAPTAB LIMITED Intrinsic Value
INNOVACAP · Healthcare · Current price ₹962.7
Is INNOVA CAPTAB LIMITED undervalued?
DocStoX estimates the fair value of INNOVA CAPTAB LIMITED at ₹431 per share, versus the current market price of ₹963. That puts the stock about -55.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹194), Relative P/E (₹963), Graham floor (₹325). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹194 (bear) to ₹431 (base) to ₹963 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹963 versus an intrinsic value of ₹431, INNOVA CAPTAB LIMITED currently offers -55.3% of negative margin (i.e. a premium).
More on INNOVA CAPTAB LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.